REG - Hemogenyx Pharma Plc - Presentation at CBD S&T Conference

Hemogenyx PharmaceuticalsAnnouncement

28/08/2024 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240828:nRSb8260Ba&default-theme=true

RNS Number : 8260B  Hemogenyx Pharmaceuticals PLC  28 August 2024

 

 28 August 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Presentation at CBD S&T Conference

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical-stage
biopharmaceutical group developing treatments for cancers and viral diseases,
is pleased to announce its participation in the 2024 Chemical and Biological
Defense Science & Technology ("CBD S&T (https://cbdstconference.com/)
") Conference, which will be held on December 2-5, 2024, in Fort Lauderdale,
FL.

 

The Company competed for a presentation slot and was invited to present its
work on its proprietary Chimeric Bait Receptor ("CBR") platform for combating
viral infections. The presentation is entitled "Chimeric Bait Receptor (CBR)
for Reprogramming of Myeloid Cells to Target and Eliminate Emerging Viral
Infections".

 

The Company's CBR platform is an advanced immunotherapy designed to program or
redirect innate immune cells, such as macrophages, to eliminate specific types
of cancer as well as to combat infections from both existing and emerging
viral threats. The Company's presentation at the CBD S&T conference will
focus on the use of the CBR platform for combating viral infections.

 

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented: "Our presentation at the CBD S&T conference will provide the
Company with an opportunity to further establish its unique position in the
rapidly evolving field of biodefense. It will also allow us to exchange ideas
with like-minded biodefense experts, potential collaborators, and investors."

 

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

 

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments for life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an engine for
novel product development.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFIATSIDFIS